ASH 2023 | MAIC of cilta-cel vs ide-cel in R/R multiple myeloma treated with 2-4 prior lines of therapy
Noffar Bar, MD, Yale School of Medicine, New Haven, CT, discusses an unanchored matching-adjusted indirect comparison (MAIC) of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory (R/R) multiple myeloma (MM) who have been treated with 2-4 prior lines of therapy. The MAIC used data from three clinical trials investigating these CAR T-cell therapies: CARTITUDE-1 (NCT03548207), CARTITUDE-4 (NCT04181827), and KarMMa-3 (NCT03651128) to compare efficacy and patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
